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Abstract
Industrial biotechnology employs the controlled use of microorganisms for the production of
synthetic chemicals or simple biomass that can further be used in a diverse array of applications
that span the pharmaceutical, chemical and nutraceutical industries. Recent advances in
metagenomics and in the incorporation of entire biosynthetic pathways into Saccharomyces
cerevisiae have greatly expanded both the fitness and the repertoire of biochemicals that can be
synthesized from this popular microorganism. Further, the availability of the S. cerevisiae entire
genome sequence allows the application of systems biology approaches for improving its enormous
biosynthetic potential. In this review, we will describe some of the efforts on using S. cerevisiae as
a cell factory for the biosynthesis of high-value natural products that belong to the families of
isoprenoids, flavonoids and long chain polyunsaturated fatty acids. As natural products are
increasingly becoming the center of attention of the pharmaceutical and nutraceutical industries,
the use of S. cerevisiae for their production is only expected to expand in the future, further allowing
the biosynthesis of novel molecular structures with unique properties.
Introduction
Microbial biosynthesis of natural products is an emerging
area of metabolic engineering and industrial biotechnol-
ogy that offers significant advantages over conventional
chemical methods or extraction from biomass. Lower
energy requirements, lower CO2  emissions, less toxic
waste in the form of solvents and metal catalysts, simpler
purification schemes, renewable feed stocks such as corn
or soybeans, and the general ability of enzymes to per-
form chiral synthesis are among the improvements to be
gained by microbial synthesis.
Within this context, almost 10 years since the publication
of its entire genome sequence [1], Saccharomyces cerevisiae,
remains the key model eukaryotic organism, with several
features that make it a useful tool for both industrial
applications and research:
1. It grows easily and adapts well in controlled fermenta-
tion environments.
2. Powerful tools for genetic engineering have been exten-
sively developed and are readily available [2-4].
3. It is nonpathogenic and has been used since ancient
times in food technology.
4. Unlike bacteria that require extensive protein engineer-
ing [5,6], yeast can readily express functional type II P450
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monooxygenases, required for the biosynthesis of higher
eukaryotic secondary metabolites [7,8].
Moreover, the availability of the entire genome sequence
has made possible the collection of comprehensive infor-
mation that allows a systems biology approach towards
strain development and optimization [9-11]. As such, S.
cerevisiae truly appears to be an ideal production platform
for important secondary metabolites, such as natural
products.
Natural products tend to encompass a wide array of small
molecules derived from both eukaryotic (plants, marine
organisms) and prokaryotic species. Their chemical struc-
ture has been fine-tuned through billions of years of evo-
lution to serve specific functions in living organisms.
Many natural products are high-value chemicals, since
only small quantities can be isolated from their native
biosynthetic organisms with the majority of them utilized
as therapeutic agents for (among others) infectious dis-
eases and cancer. The advent of genomics and metagen-
omics has allowed not only the discovery of a huge
number of new promising metabolites, but also the eluci-
dation of their biosynthetic pathways. As a result, the use
of well-characterized hosts for their efficient, large scale
production is now possible.
Since presenting the entire range of natural product bio-
synthesis in S. cerevisiae would require an extensive
amount of space, in the next few paragraphs we will only
highlight some of the most characteristic work in this area.
Isoprenoid biosynthesis
Isoprenoids (also known as terpenoids) belong to a vast
group of secondary metabolites [12] that include caroten-
oids, sterols, polyprenyl alcohols, ubiquinone (coenzyme
Q), heme A and prenylated proteins. They are of valuable
commercial interest as food colorants and antioxidants
(carotenoids), aroma and flavor enhancers (terpenes),
nutraceuticals (ubiquinone), and antiparasitic and anti-
carcinogenic compounds (taxol) [13-15].
All isoprenoids are synthesized from a universal com-
pound called isopentenyl diphosphate (IPP). The first
pathway to IPP, the mevalonic acid (MVA) pathway, was
first described by Bloch and Lynen [16,17]. In yeast, the
mevalonate pathway (Figure 1) is chiefly employed to
form ergosterol (provitamin D2) which is an essential part
of the yeast membrane and provides membrane permea-
bility and fluidity [18-21].
Some of the most important isoprenoids and their engi-
neered biosynthesis in S. cerevisiae will be further
described.
Taxol
Taxol is a complex substituted terpenoid that was first iso-
lated from the bark of Pacific yew (Taxus brevifolia). It is a
potent anticancer agent that has been approved for the
treatment of refractory ovarian and metastatic breast can-
cer. Currently, the demand for taxol greatly exceeds the
supply that can be isolated from its natural sources [22].
Very elegant total chemical syntheses of taxol have been
Biosynthesis of isoprenoids by the mevalonate pathway Figure 1
Biosynthesis of isoprenoids by the mevalonate pathway. IPP: isopentenyl pyrophosphate; ERG10: acetoacetyl-CoA 
ligase; ERG13: 2-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoA synthase); HMG1 and HMG2: 2-hydroxy-3-methylglu-
taryl-CoA reductases; ERG12: mevalonate kinase; ERG8: phosphomevalonate kinase; MVD1: diphosphomevalonate decarboxy-
lase; IDI1: isopentenyl pyrophosphate:dimethylallyl diphosphate isomerase; ERG20: farnesyl diphosphate synthase.Microbial Cell Factories 2006, 5:20 http://www.microbialcellfactories.com/content/5/1/20
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developed but, because of low yields and high costs, none
of these approaches is suitable for its commercial produc-
tion. Similarly, Taxus cell cultures have yet to reach com-
mercialization due to low and unstable productivity [23].
With the partial elucidation of the taxol biosynthetic path-
way the possibility of taxadiene (a taxol biosynthetic
intermediate) biosynthesis in Escherichia coli was success-
fully demonstrated [24]. One major limitation with that
approach however is that the prokaryotic E. coli can not
functionally express the P450 enzymes that widely partic-
ipate in the taxol biosynthetic pathway. Hence, S. cerevi-
siae  was chosen as an alternative, since it has been
reported that yeast was successfully employed as host for
the engineered, multi-step production of other (meval-
onate-derived) terpenoids, including steroids and carote-
noids [23].
Recently, partial taxol biosynthetic pathway was con-
structed in S. cerevisiae by expressing five sequential path-
way steps leading from primary isoprenoid metabolism to
the intermediate taxadien-5α-acetoxy-10β-ol (Figure 2)
[23]. The Taxus cuspidate genes the yeast host expressed
included geranylgeranyl disphosphate synthase (GGPPS),
taxadiene synthase (TS), cytochrome P450 taxadiene 5α-
hydroxylase (TYH5a), taxadienol 5α-O-acetyl transferase
(TAT) and taxoid 10β-hydroxylase (THY10b). The recom-
binant strain produced taxadiene at 1.0 mg/L while taxad-
ien-5α-ol was produced in very small amounts (~25 µg/
L). These results suggest that the first two enzymes
(GGPPS and TS) cooperated well with each other and that
the metabolic flux was reduced at the 5α-hydroxylation
step, which is catalyzed by a cytochrome P450 hydroxy-
lase [23]. It is anticipated that overexpressing Taxus P450
oxygenases with their corresponding P450 reductases in
Taxol biosynthesis pathway Figure 2
Taxol biosynthesis pathway. GGPPS: Genranylgenranyl diphosphate synthase; TS: taxadiene synthase; TYHa: taxadiene 5α-
hydroxylase; TAT: taxa-4(20), 11(12)-dien-5a-ol-O-acetyltransferase; TYHb: taxane 10β-hydroxylase; TBT: taxane 2a-O-ben-
zoyltransferase; DBAT: 10-deacetyl baccatin III-O-acetyltransferase. PAM: phenyalanine aminomutase. Multiple arrows indicate 
several as of yet undefined steps. Red text indicates a cytochrome P450 enzyme.Microbial Cell Factories 2006, 5:20 http://www.microbialcellfactories.com/content/5/1/20
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the yeast host would improve the overall production
amounts [25].
Although the metabolic engineering of taxol biosynthesis
in yeast has only begun, the application of new protein
engineering techniques to improve rate-controlling
enzymes appears promising. As a result, S. cerevisiae
recombinant strains not only provide a new approach for
taxol production, but also create platforms that allow the
synthesis of taxol analogues and other rare taxoids for
clinical evaluation [15].
Carotenoids
Carotenoids are a subfamily of isoprenoids that are the
most widely distributed yellow, orange and red natural
pigments synthesized in bacteria, algae, fungi [26]. Com-
mercially carotenoids such as β-carotene and astaxanthin
are used as food colorants, animal feed supplements and
for nutritional and cosmetic purposes. More recently, car-
otenoids have received attention for their significant anti-
oxidant activities and for playing an important role in
inhibiting the onset of chronic diseases [27-30]. The
majority of the 600 known structures of carotenoids are
C40-carotenoids while a few bacterial carotenoids exist
with 30, 45 or 50 carbon atoms (Figure 3).
Carotenoid pathways have been successfully introduced
into noncarotenogenic microbes such as E. coli and S. cer-
evisiae [31-35]. Since S. cerevisiae produces ergosterol as its
principal isoprenoid from farnesyl diphosphate (FPP), it
would be possible to redirect the flux of FPP away from
ergosterol into genranylgenranyl diphosphate (GGPP)
and subsequent carotenoids. Indeed, the insertion of a
plasmid containing Erwinia uredovora GGPP synthase
(crtE), phytoene synthase (crtB) and phytoene desaturase
(crtI) genes under the control of various S. cerevisiae pro-
moters allowed S. cerevisiae to produce lycopene (113 µg/
g dry weight) [35]. In addition, S. cerevisiae harboring a
plasmid containing the additional E. uredovora lycopene
cyclase (crtY) gene resulted in the production of β-caro-
tene (103 µg/g dry weight) [35].
Sterols
Sterols are important for the physiology of eukaryotic
organisms as they form part of the cellular membrane
where they modulate their fluidity and function and par-
ticipate as secondary messengers in developmental signal-
ing [36]. In yeast, ergosterol is the main sterol and is
analogous to cholesterol in mammalian cells [19]. Ergos-
terol is also an economically important metabolite, as it is
the precursor for the production of vitamin D2. The com-
plex production of sterols in yeast is tightly regulated at
multiple levels. One of the major bottlenecks is the reac-
tion catalyzed by HMG-CoA (Figure 1). Overexpression of
a truncated Hmg1p led to a 40-fold increase of HMG-CoA
activity and resulted in an increased accumulation of
squalene, an intermediate towards ergosterol, of up to
5.5% of dry matter [37]. However, there was little effect
on the overall ergosterol production, suggesting addi-
tional regulation further down the pathway to ergosterol.
More recently, overexpression of the post-squalene genes
led to the discovery of two additional bottlenecks in the
pathway, namely squalene epoxidase (Erg1p) and sterol-
14alpha-demethylase (Erg11p). Overexpression of Erg1p,
Erg11p and a truncated Hmg1p led to a three-fold
increase of sterol content over the wild-type [38]. How-
ever, 90% of the sterol content was esterfied sterol inter-
mediates and not ergosterol. Obviously, further
regulatory mechanisms are at play preventing the quanti-
tative accumulation of ergosterol.
Besides ergosterol, several sterol intermediates are of bio-
logical importance including methylated sterol intermedi-
ates that activate meiosis [4,4-dimethyl-5alpha-cholesta-
8,14,24-trienol (FF-MAS) and 4,4-dimethyl-5alpha-
cholesta-8,24-dienol (T-MAS)] [39]. FF-MAS is the sub-
Carotenoid biosynthesis pathway Figure 3
Carotenoid biosynthesis pathway. IPP: Isopentyl pyro-
phosphate; crtE: geranylgenranyl diphosphate synthase; crtB: 
phytoene synthase; crtI: phytoene desaturase; crtZ: β-caro-
tene hydroxylase; crtX: zeaxanthin glucosylase; crtM: dehy-
drosqualene synthase; crtN: dehydrosqualene desaturase; 
crtEb: lycopene elongase; crtYe/Yf: heterodimeric deca-
prenoxanthin synthase.Microbial Cell Factories 2006, 5:20 http://www.microbialcellfactories.com/content/5/1/20
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strate of Erg24p and T-MAS is the substrate of Erg25p.
While supplying exogenous ergosterol or cholesterol,
engineered strains with abolished heme biosynthesis and
deleted ERG25 gene accumulated T-MAS (1.3 mg/L) while
deleting both ERG24 and ERG25 genes accumulated FF-
MAS (5.4 mg/L) [40]. Zymosterol is another intermediate
of interest as it is the precursor of cholesterol lowering
substances. By deleting sterol transmethylase (ERG6) and
8-carbon sterol isomerase (ERG2), zymosterol accumu-
lated as the major sterol [41].
Strains able to produce sterols not native to yeast have
also been engineered. For example, a single mutation of
∆24(25)- to ∆24(28)-sterol methyl transferase (SMT) enzyme
from S. cerevisiae resulted in a protein able to synthesize
mono- and bis-C24-alkylated side chains of several
∆24(25)- and ∆24(28)-sterols [42]. Also, several 24-ethyl ster-
ols and 24-ethylidene sterols were produced in engi-
neered S. cerevisiae carrying a sterol 24-methyltransferase
gene from the Arabidopsis thaliana [43].
Long chain Polyunsaturated Fatty Acids (PUFA) 
biosynthesis
PUFAs are fatty acids of 16 or more carbon long chains
with two or more double bonds (Figure 4). Normal cellu-
lar function is dependent upon PUFAs as they are signal-
ing molecules and regulators of membrane fluidity [44].
In general, fatty acids can be synthesized endogenously;
however, PUFAs are necessary part of a diet for normal
growth and development because mammals are incapable
of synthesizing the essential linoleic acid (18:2ω6) [45],
and ω-3 and ω-6 fatty acids. Diets rich in PUFAs were
shown in studies to protect infants from cardiovascular
disease, and were beneficial for the development of retina
and brain functions [44,46].
PUFAs are commercially obtained primarily from seeds,
marine animals, microalgae and microheterotrophs. Over
the past few years, progress has been made in engineering
S. cerevisiae for fatty acid production. More specifically, in
S. cerevisiae, only saturated (mainly 16:0 and 18:0) and
mono-saturated (18:1ω9) fatty acids, are synthesized de
novo [47,48]. Formation of PUFAs requires the expression
of heterogeneous genes to introduce additional double
bonds (eg. ∆6-, ∆12-desaturases) and produce enzymes for
chain elongation (elongases) [18,49].
A number of desaturases from a variety of sources have
been discovered and functionally expressed in S. cerevisiae
to produce PUFAs. For example, expression of the ∆6-
desaturase from Mucor rouxii in yeast resulted in an accu-
mulation of γ-linolenic acid (18:3ω6) as 7.1% of the total
fatty acids when fed with linoleic acid (18:2ω6) [50].
Introducing ∆12-desaturases from various sources allows
for the accumulation of linoleic acid (18:2) and hexadec-
adienoic acid (16:2) fatty acids [51-55]. Co-expression of
both a ∆6-desaturase and a ∆12-desaturase from M. alpine
resulted in endogenous γ-linolenic acid (18:3ω6) as high
as 8% of total fatty acid content [56].
The range and length of PUFAs synthesized in yeast have
increased with the expression of various higher-eukaryote
genes. For example in yeast, arachidonic acid and eicosap-
entaenoic acid can be produced by coexpression of ∆5-
and ∆6-desaturases with a ∆6-elongase in the presence of
exogenously supplied linoleic acid and linolenic acid,
respectfully [57,58]. A desaturase from zebrafish (Danio
rerio) displayed both ∆5  and  ∆6-desaturase activity
expressed in S. cerevisiae by converting linoleic acid
(18:2ω6) and α-linolenic acid (18:3ω3) into their respec-
tive ∆6-desaturase products, γ-linolenic acid (18:3ω6) and
stearidonic acid (18:4ω3) and by converting di-homo-γ-
linoleic acid (20:3ω6) and eicosatetraenoic acid (20:4ω3)
to their ∆5-desaturase products, arachionic acid (20:4ω6)
and eicosapentaenoic acid (20:5ω3) [59]. The cDNAs
encoding desaturase and elongase enzymes from various
marine and fresh water fish, a primary source of fatty acids
continue to be characterized [60,61].
Flavonoid biosynthesis
Flavonoids are a diverse group of plant secondary metab-
olites that contain a 15-carbon phenylpropanoid core,
which is extensively modified by rearrangement, alkyla-
tion, oxidation and glycosylation [62]. These fascinating
compounds possess extraordinary antioxidant activity
and they also exhibit estrogenic, antiviral, antibacterial
and anti-cancer activities [63].
Metabolic pathways of ω3 and ω6 fatty acids Figure 4
Metabolic pathways of ω3 and ω6 fatty acids.Microbial Cell Factories 2006, 5:20 http://www.microbialcellfactories.com/content/5/1/20
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The health-protecting effects of flavonoids have stimu-
lated significant research toward the elucidation of their
biosynthetic networks (Figure 5), as well as the develop-
ment of production platforms using well-characterized
hosts, such as E. coli and S. cerevisiae [64]. The ability of
yeast to express type II P450 hydroxylases, many of which
are involved in flavonoid biosynthesis, makes it an attrac-
tive production platform, even though a recent report has
demonstrated the functional expression of one such
enzyme in E. coli [65]. Ro and Douglas [66] were the first
to connect the two initial enzymes involved in phenylpro-
panoid pathway, namely phenylalanine ammonia lyase
(PAL) and cinnamate 4-hydroxylase (C4H) in S. cerevisiae
together with a cytochrome P450 reductase. The carbon
flux through the multienzyme system from phenylalanine
to p-coumaric acid in yeast was evaluated in their study.
Later, two independent studies demonstrated the biosyn-
thesis of flavanones, the common precursors of the vast
majority of flavonoids, in S. cerevisiae. The first study by
Jiang et al. [67] described the production of monohydrox-
ylated naringenin and unhydroxylated pinocembrin at
levels of 7 mg/L and 0.8 mg/L respectively. The second
study by Yan et al. [68] reported the biosynthesis of fla-
vanones in S. cerevisiae by constructing a gene cluster that
included C4H from A. thaliana, 4cL-2 from parsley, and
CHI-A (encoding for chalcone isomerase) and chs from
petunia. The recombinant S. cerevisiae strain was fed with
phenylpropanoid acids and produced naringenin (28.3
mg/L), pinocembrin (16.3 mg/L) and the trihydroxylated
flavanone eriodictyol (6.5 mg/L). In a continuation of the
previous work, Leonard et al demonstrated the biosynthe-
sis of the flavone molecules apigenin, luteolin and chrysin
by exploring the expression of a soluble flavone synthase
I (FSI) and a membrane bound flavone synthase II (FSII)
in yeast cells. The effect of the yeast P450 reductase over-
expression on flavone biosynthesis was also investigated
[8]. Recently, Ralston et al. [69] reported the partial recon-
struction of isoflavonoid biosynthesis in S. cerevisiae by
using different types of CHI and an isoflavone synthase
(IFS) from soybean (Glycine max).
With the rapid unraveling of the flavonoid biosynthetic
pathways a wide array of flavonoid compounds, natural
and unnatural, is expected to be produced from S. cerevi-
siae in the near future. In addition, the natural coloration
of some of the flavonoid molecules (anthocyanins) opens
up the possibility of using directed evolution for protein
activity fine tuning and thus further improvement of the
overall productivity [64].
Conclusion
Ever since the era of recombinant DNA technology for
natural product biosynthesis emerged [70], S. cerevisiae
has remained the production platform of choice for many
fine chemicals, including natural products. The rapid elu-
cidation of biosynthetic pathways made possible through
advanced genomic tools, has made natural product again
the molecules of choice for drug development. Indeed,
half of the drugs currently in clinical use are natural prod-
ucts and it is expected that the market size of biotech-
derived small molecules will exceed 100 billion US$ in
2010 and 400 billion US$ in 2030 [71,72]. As such, we
believe that S. cerevisiae will not only remain the cell fac-
tory of choice but that the application of powerful systems
Flavonoid biosynthesis pathway Figure 5
Flavonoid biosynthesis pathway. PAL: Phenylalanine 
ammonia-lyase; C4H: cinnamate-4-hydroxylase; 4CL: 4-cou-
maroyl:CoA-ligase; CHS: chalcone synthase; CHI: chalcone 
isomerase; FSI: flavone synthase; FSII: cytochrome P450 fla-
vone synthase; IFS: cytochrome P450 isoflavone synthase; 
FHT: flavanone 3β-hydroxylase; DFR: dihydroflavonol 4-
reductase; LAR: leucoanthocyanidin synthase; ANS: anthocy-
anidin synthase; 3GT: UDPG-flavonoid 3-O-glucosyl trans-
ferase. Red text indicates cytochrome P450 enzymes.Microbial Cell Factories 2006, 5:20 http://www.microbialcellfactories.com/content/5/1/20
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biology approaches will facilitate its expanded role in
industrial applications [73-75].
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